Doctors' perceptions of psoriasis therapies vary

February 7, 2013
Doctors' perceptions of psoriasis therapies vary
Doctors who treat patients with psoriasis show wide variation in their beliefs about the safety and effectiveness of psoriasis treatments, according to a study published in the February issue of the Journal of the American Academy of Dermatology.

(HealthDay)—Doctors who treat patients with psoriasis show wide variation in their beliefs about the safety and effectiveness of psoriasis treatments, according to a study published in the February issue of the Journal of the American Academy of Dermatology.

Katrina Abuabara, M.D., from the University of Pennsylvania Perelman School of Medicine in Philadelphia, and colleagues surveyed 246 members of the National Psoriasis Foundation and 141 members of the American Academy of Dermatology about the safety and effectiveness of psoriasis treatments.

The researchers found that , ustekinumab, cyclosporine, and adalimumab were regarded as being most likely to clear skin in three months (67 to 75 percent). Etanercept, , ultraviolet B, and ustekinumab were regarded as being the least likely to produce side effects requiring discontinuation of treatment (9 to 11 percent). In both cases, up to 49 percent "didn't know" the effectiveness or the likelihood of side effects, and the coefficients of variation were higher for the perceived likelihood of side effects. There were few significant correlations between perceptions and respondent characteristics, and perceptions could not be consistently predicted by treatment preference.

"Psoriasis providers demonstrate wide variation in their perception of the effectiveness and especially safety of systemic treatments," Abuabara and colleagues conclude.

Several authors disclosed to the pharmaceutical industry.

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

UVB preferred for treatment of moderate to severe psoriasis

February 24, 2012

(HealthDay) -- Ultraviolet B (UVB) is preferred by dermatologists for first-line treatment of moderate to severe psoriasis in both healthy male and female patients, according to a study published in the March issue of the ...

Study compares effectiveness of psoriasis treatments

April 20, 2012

(HealthDay) -- The effectiveness of therapies for psoriasis is variable, and may be lower in real-world settings than in trial settings, according to a study published in the April issue of the Archives of Dermatology.

Many psoriasis patients undertreated for CV risk factors

June 22, 2012

(HealthDay) -- A large proportion of patients with moderate-to-severe plaque psoriasis are underdiagnosed and undertreated for cardiovascular (CV) risk factors, according to a study published in the July issue of the Journal ...

Short/long-term analyses deem etanercept safe for psoriasis

July 29, 2012

(HealthDay) -- Etanercept treatment is well tolerated for psoriasis, with no indication of dose-related or cumulative toxicity in short- or long-term analyses, according to a study published in the August issue of the Journal ...

Reasons for discontinuation vary by psoriasis treatment

August 10, 2012

(HealthDay) -- The reasons for discontinuation of commonly used treatments for psoriasis vary by treatment, according to a study published online July 30 in the Journal of the American Academy of Dermatology.

Recommended for you

Experimental MERS vaccine shows promise in animal studies

July 28, 2015

A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines. ...

Can social isolation fuel epidemics?

July 21, 2015

Conventional wisdom has it that the more people stay within their own social groups and avoid others, the less likely it is small disease outbreaks turn into full-blown epidemics. But the conventional wisdom is wrong, according ...

Lack of knowledge on animal disease leaves humans at risk

July 20, 2015

Researchers from the University of Sydney have painted the most detailed picture to date of major infectious diseases shared between wildlife and livestock, and found a huge gap in knowledge about diseases which could spread ...

IBD genetically similar in Europeans and non-Europeans

July 20, 2015

The first genetic study of inflammatory bowel disease (IBD) to include individuals from diverse populations has shown that the regions of the genome underlying the disease are consistent around the world. This study, conducted ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.